Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Jazz Pharmaceuticals plc reports developments across a global biopharma portfolio focused on rare diseases, including epilepsies, cancers and sleep disorders. Recurring updates cover commercial performance for Xywav, Epidiolex and oncology products, plus medical-conference data and real-world evidence for neuroscience and oncology programs.
Company news also includes regulatory and clinical progress for Ziihera (zanidatamab-hrii) in HER2-expressing tumors, including gastroesophageal adenocarcinoma and biliary tract cancer, along with research involving Zepzelca, Modeyso and other pipeline candidates. Updates frequently address financial results, guidance, investor conferences, collaborations and portfolio strategy.
Jazz Pharmaceuticals (Nasdaq: JAZZ) agreed to acquire privately held Actio Biosciences for an $820 million upfront payment plus up to $500 million in approval and sales milestones, adding ABS-1230, a clinical-stage, potential first-in-class KCNT1 ion channel inhibitor for KCNT1+ epilepsy, an ultra-rare disease with no FDA-approved therapies.
The ongoing Phase 1b/2a KYRON trial of ABS-1230 is intended as the U.S. registrational study and the drug has FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations, and acceptance into the FDA’s Rare Disease Evidence Principles (RDEP) program. At closing, Actio will spin out a new rare-neurology company retaining assets such as ABS-0871 for Charcot-Marie-Tooth type 2C, funded by existing investors, in which Jazz will receive a minority stake. The all-cash transaction, unanimously approved by both boards, is expected to close by the fourth quarter of 2026, financed with cash on hand and existing facilities.
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported record 2Q26 total revenues of $1.21 billion, up 16% year over year, with GAAP EPS of $2.78 and non-GAAP adjusted EPS of $5.71. Xywav sales grew 13% to $471 million, Epidiolex/Epidyolex 16% to $292 million, and Zepzelca 42% to $106 million, while Modeyso contributed $48 million and Ziihera $15 million in 2Q26.
According to Jazz Pharmaceuticals, 1H26 cash from operations reached $824 million, with cash and investments of $2.2 billion and long‑term debt of $4.4 billion after repaying $1.0 billion of exchangeable notes. The company raised 2026 revenue guidance to $4.60–$4.75 billion and highlighted upcoming FDA action for Ziihera in HER2+ 1L GEA on August 25, 2026, plus Breakthrough Therapy designation in HER2‑positive colorectal cancer.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close of U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to review results and provide a business and financial update.
Interested participants can register via the Investors section of the Jazz Pharmaceuticals website and are encouraged to do so at least 15 minutes before the webcast. A replay will be available on the same site. Jazz describes itself as a global biopharma company focused on medicines for rare diseases, epilepsies, cancers and sleep disorders.
AbCellera (Nasdaq: ABCL) and Jazz Pharmaceuticals announced a preclinical collaboration, option and license agreement to discover next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors.
AbCellera receives $56 million upfront, up to $28 million for a third program, and may earn up to $792 million per program in potential option, development, regulatory and commercial milestone payments, plus tiered royalties on net sales.
Jazz Pharmaceuticals (Nasdaq:JAZZ) presented 11 late-breaking data sets at SLEEP 2026 on Xywav in narcolepsy and idiopathic hypersomnia. Findings highlight individualized dosing optimization, real-world feasibility in over 13,000 patients, and cardiometabolic markers potentially affected by Xywav’s low-sodium formulation, including blood pressure, lipids, and sodium-related symptoms.
Jazz Pharmaceuticals (Nasdaq:JAZZ) reported top-line Phase 3 LAGOON results for Zepzelca (lurbinectedin) in second-line small cell lung cancer. The trial did not meet its primary overall survival endpoint for Zepzelca alone or with irinotecan versus topotecan/irinotecan. No new safety signals were seen, and safety profiles matched known data.
Overall median OS was 8.7 months (Zepzelca), 10.9 months (Zepzelca+irinotecan), and 10.7 months (control). Jazz said LAGOON does not affect Zepzelca’s U.S. first-line maintenance approval or its 2026 guidance.
Jazz Pharmaceuticals (Nasdaq:JAZZ) will present 21 abstracts, including 11 late-breaking, at SLEEP 2026 (June 14-17, Baltimore) focused on Xywav for narcolepsy and idiopathic hypersomnia.
Presentations cover DUET, LYRICAL, XYLO and other studies on sleep inertia, hypersomnolence, quality of life, cardiovascular biomarkers and individualized low-sodium oxybate dosing.
Jazz (NASDAQ:JAZZ) reported Phase 3 HERIZON-GEA-01 results in HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma using Ziihera (zanidatamab-hrii) plus chemotherapy, with or without Tevimbra (tislelizumab).
Zanidatamab combinations improved median PFS (12.4 vs 8.1 months) and OS (up to 26.4 vs 19.2 months), with consistent benefit across PD-L1 subgroups, including PD-L1-negative patients (OS 29.7 vs 15.8 months). Safety was consistent with known component profiles.
Jazz Pharmaceuticals (Nasdaq:JAZZ) announced that management will join fireside chats at three upcoming investor events: the 2026 RBC Global Healthcare Conference on May 19, 2026 at 8:00 a.m. ET, the Cowen 7th Annual Oncology Innovation Summit on May 27, 2026 at 2:00 p.m. ET, and the 2026 Jefferies Global Healthcare Conference on June 3, 2026 at 10:30 a.m. ET.
Audio webcasts will be accessible through the Investors section of Jazz Pharmaceuticals’ website, with replays available for 30 days.
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported 1Q26 results: total revenues $1.07B (+19% YoY), GAAP EPS $4.43 and non-GAAP EPS $6.34, and $408M cash from operations. Zanidatamab sBLA for HER2+ 1L GEA received Priority Review with a PDUFA date of Aug 25, 2026. Xywav, Epidiolex, Zepzelca and Modeyso drove revenue growth. The company reaffirmed 2026 guidance of $4.25–$4.50B revenues and provided ranges for margins, SG&A, R&D and tax rate assumptions.